OncoTracker Signs Licensing Agreement with Juno Therapeutics; Provides Update on Internal Development

Los Angeles, CA – December 4, 2017 — OncoTracker, Inc., a private medical diagnostics company, announced a license agreement with Juno Therapeutics (NASDAQ: JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, to advance its program in multiple myeloma using gamma secretase inhibitors (GSIs) in combination with BCMA-directed CAR T cells. …